Skip to main content

Cormorant Asset Management — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

205
Companies
$20.8B
Total invested
$136.8M
Avg. check
16
Industries
Biotechnology 23Health Care 17Therapeutics 13Medical 9Pharmaceutical 7Biopharma 5+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 205
Icosavax
May 2023

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Biotechnology · Seattle$67.8M Post-IPO Equity
Quince Therapeutics
May 2026

Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.

Biotechnology · South San Francisco$115.0M Post-IPO Equity
Antares Therapeutics
May 2025

Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.

Biopharma · Boston$177.0M Series A
MOMA Therapeutics
May 2022

MOMA Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$150.0M Series B
Valneva
April 2026

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.

Biotechnology · Saint-herblain$43.1M Post-IPO Equity
GH Research
April 2026

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$117.5M Post-IPO Equity
Oruka Therapeutics
April 2026

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$700.4M Post-IPO Equity
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Edgewise Therapeutics
April 2025

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Biopharma · Boulder$200.0M Post-IPO Equity
Ventus Therapeutics
April 2023

Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.

Biotechnology · Waltham$150K Grant
Terremoto Biosciences
April 2026

Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.

Biotechnology · San Francisco$108.0M Series C
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Spyre Therapeutics
April 2026

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$403.0M Post-IPO Equity
Korro Bio
March 2026

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

Biotechnology · Cambridge$85.0M Post-IPO Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post-IPO Equity
Orchard Therapeutics
March 2023

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

Biotechnology · London$34.0M Post-IPO Equity
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post-IPO Equity
OnKure Therapeutics
March 2026

OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.

Biotechnology · Boulder$150.0M Post-IPO Equity
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post-IPO Equity
Supira Medical
March 2025

Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions.

Health Care · Los Gatos$120.0M Series E
Tessera Therapeutics
March 2026

Tessera Therapeutics develops gene writing technology designed to modify DNA sequences within human cells for therapeutic use.

Biopharma · CambridgeGrant
Ovid Therapeutics
March 2026

Ovid Therapeutic's purpose is to solve intractable medical problems.

Biopharma · New York$60.0M Post-IPO Equity
Latigo Biotherapeutics
March 2025

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

Biotechnology · Thousand Oaks$150.0M Series B
Twist Bioscience
February 2022

Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries.

B2B · San Francisco$250.0M Post-IPO Equity

Where Cormorant Asset Management invests

Biotechnology23
Health Care17
Therapeutics13
Medical9
Pharmaceutical7
Biopharma5

About Cormorant Asset Management's portfolio

How many companies has Cormorant Asset Management invested in?

Cormorant Asset Management has invested in 205 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Cormorant Asset Management invest in?

Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.

What is Cormorant Asset Management's largest investment?

Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $20.8B.

What is the average investment size for Cormorant Asset Management?

Cormorant Asset Management's average investment size is $136.8M across its portfolio of 205 companies.

What are Cormorant Asset Management's most recent investments?

Recent Cormorant Asset Management portfolio additions include Icosavax, Quince Therapeutics, Antares Therapeutics, MOMA Therapeutics, Valneva. These companies were founded in 2020 or later.

Reach the founders behind these 205 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →